Bioptigen, a spin-out from Duke University’s Biomedical Engineering Department, has raised another $500,000 in financing.
The Piedmont Angel Network Two fund, which had participated in the Series A $1.3 million round for Bioptigen, announced its participating in the B round on Thursday.
Other Series A investors also participated in the new round, but they were not disclosed. Bioptigen raised $1.4 million in the A round.
Earlier this year Bioptigen received Food and Drug Administration approval to begin marketing its non-invasive eye scanner.
The FDA-approved imaging system is designed to deliver micro-scale, 3D images of the retina and other eye surfaces 50 times faster than other scanners. The company believes the scanners, called spectral domain optical coherence tomography imaging systems, or SDOCT, will be useful in exams for eye diseases such as glaucoma.
Bioptigen is also developing other imaging systems for use inside or outside of the body as well as image-processing software.
The B round funds will be used to help the company introduce its scanner at the American Academy of Ophthalmology conference in November.
Bioptigen plans to raise a total of $2 million in the B round.
